On August 20, 2024, GSK plc announced receiving the US FDA Breakthrough Therapy Designation for its investigational drug GSK5764227, aimed at treating advanced small-cell lung cancer, which currently has very limited treatment options.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.